Blog — Latest Peptide Articles - Page 37 of 39

EC Approves First Teriparatide Biosimilar: What Zandoriah Means for Peptide Manufacturing

Industry & Market

Peptide Proof Editorial

-

June 18, 2026

0

EC Approves First Teriparatide Biosimilar: What Zandoriah Means for Peptide Manufacturing

Peptide Proof — Evidence-Based Peptide Intelligence. Independent analysis. No paywall.

Here’s What Happened

The European Commission has approved CinnaGen’s Zandoriah — teriparatide biosimilar — for the treatment of osteoporosis in adults, marking a significant regulatory milestone for the peptide biosimilar market. Teriparatide — recombinant human parathyroid hormone (PTH 1–34), a 34-amino acid peptide — has been a mainstay anabolic osteoporosis therapy since Eli Lilly’s Forteo gained approval in 2002. The EC decision signals that peptide biosimilars are entering a new phase of regulatory maturity, with potentially far-reaching implications for manufacturing capacity, pricing dynamics, and CDMO strategy across the broader peptide therapeutics field.

Context

Teriparatide is a truncated form of parathyroid hormone — specifically the biologically active N-terminal 1–34 amino acid fragment of the 84-amino acid native hormone. Unlike antiresorptive agents — bisphosphonates, denosumab — that slow bone loss, teriparatide is anabolic: it stimulates new bone formation when administered intermittently. This mechanism makes it uniquely valuable for patients with severe osteoporosis who have already suffered fractures or failed other therapies.

Eli Lilly’s Forteo dominated the market for nearly two decades, generating peak annual sales of approximately 1.4 billion dollars before losing US patent exclusivity in 2019. Since then, the terrain has shifted: the US FDA approved its first teriparatide biosimilar (from Alvogen/Teva) in 2023, and the EMA has now followed with CinnaGen’s Zandoriah receiving EC approval in June 2026. CinnaGen, an Iran-based biopharmaceutical company with a growing European regulatory footprint, positions this approval as a step toward expanding biosimilar access across the EU market.

The Data

Active Ingredient | Teriparatide, also known as PTH 1–34 | Teriparatide, also known as PTH 1–34.

Sequence Length | 34 amino acids | 34 amino acids.

Molecular Weight | ~4,118 Da | ~4,118 Da.

Expression System | E. coli (recombinant) | E. coli (recombinant).

Route | Subcutaneous injection | Subcutaneous injection.

Approval Year, also known as EU | 2003 | 2026.

Manufacturer | Eli Lilly | CinnaGen.

Global Market (2026) | ~1.8 billion dollars (including all teriparatide products).

Expert Insight

Anti-Pattern: Assuming peptide biosimilars follow the small-molecule generic playbook. The single most common mistake industry analysts make is treating peptide biosimilars as interchangeable with chemically synthesized generics. Teriparatide is a recombinant peptide produced in E. coli, not a chemically synthesized small molecule. Biosimilarity for peptides requires demonstrating comparability across primary sequence, higher-order structure, post-translational modifications, and biological activity — a burden that sits between small-molecule generics and monoclonal antibody biosimilars in complexity.

Experienced peptide developers know that E. coli expression of the 34-amino acid PTH fragment is deceptively challenging. The peptide is prone to methionine oxidation (Met8, Met18), deamidation (Asn10, Asn16), and aggregation at formulation concentrations. A teriparatide biosimilar manufacturer must replicate not just the amino acid sequence but also the impurity profile, aggregation kinetics, and delivery device performance of the originator. The EC’s approval of Zandoriah confirms that CinnaGen has navigated these hurdles —. it also serves as a reminder that the analytical and CMC burden for peptide biosimilars is substantial. often underestimated by teams coming from a small-molecule background.

What Experienced Teams Know: The real manufacturing bottleneck for teriparatide biosimilars is not the fermentation step but downstream purification. The 34-mer peptide requires multiple chromatography steps (typically ion-exchange followed by reversed-phase HPLC) to achieve pharmaceutical-grade purity, and HPLC capacity remains the rate-limiting factor across the broader peptide CDMO landscape. With semaglutide and tirzepatide consuming vast amounts of preparative HPLC capacity worldwide, teriparatide biosimilar manufacturers face direct competition for purification slots — a dynamic that influences both cost of goods and time-to-market for every new peptide biosimilar entrant.

Here’s What Happened

The question is asked at every peptide conference, in every investor pitch, and by every patient who has ever hesitated at the sight of an injection pen: when will we be able to take peptide drugs as pills? The answer, stripped of the hype that pervades this topic, is: for some peptide classes, within 5 years. For most, not in our lifetimes. The distinction is not about “solving oral delivery” — it is about understanding which peptides can be economically delivered orally, and which cannot. This analysis separates the realistic from the aspirational.

The Economics of Oral Peptide Delivery

The fundamental challenge is not bioavailability — it is cost per bioavailable dose. Oral semaglutide (Rybelsus) achieves 0.8–1.2 percent oral bioavailability. To deliver 1 mg of absorbed semaglutide, patients must swallow a 14 mg tablet — meaning ninety-nine percent of the expensive peptide API is wasted. Rybelsus succeeds commercially despite this inefficiency because the addressable market (diabetes + obesity) is massive and the price point ($10,000–16,000/year) supports the cost of goods. For a peptide treating a rare disease with 10,000 patients and a $50,000/year price, the same economics do not close: the oral formulation would cost $200,000–500,000/year to manufacture, consuming the entire gross margin.

Mid-size linear, also known as 15–30 AA | Low | 2030+ | Bioavailability <0.5% at best.

PDCs / conjugates | None | Never | Cytotoxic payload; first-pass tox risk.

The data show a stark gradient: oral delivery is viable for peptides that are short, relatively hydrophobic, and address large markets. For everything else, injectable administration will remain the standard of care.

Expert Insight: The Dosing Regimen Problem

An underappreciated factor in the oral peptide debate is dosing convenience vs. injection interval. Injectable semaglutide is administered once weekly. Oral semaglutide must be taken every morning, on an empty stomach, with no more than 120 mL of water, with a 30-minute wait before eating. Real-world adherence data from a 2025 Truven Health claims analysis showed that only forty-two percent of Rybelsus patients remained on therapy at 12 months, compared to sixty-eight percent for weekly injectable semaglutide. The assumption that “oral = better adherence” does not hold when the oral dosing regimen is more burdensome than the injection schedule. A once-weekly oral peptide — currently in preclinical development at multiple companies — could change this calculation. A daily oral peptide with fasting requirements does not.

The counterintuitive reality: For many patients, a once-weekly subcutaneous injection is more convenient than a daily oral pill with fasting requirements. The peptide industry has internalized the assumption that oral delivery is the ultimate goal, but patient preference data consistently show that dosing frequency matters more than route of administration. A once-monthly injectable peptide — currently in development for GLP-1s — would likely capture more market share than a daily oral alternative.

Here’s What Happened

Between January 2020 and June 2026, the FDA approved 28 peptide-based drugs — but the distribution across therapeutic modalities tells a more revealing story than the aggregate number. Linear peptides still dominate — 17 approvals —, but macrocycles, peptide-drug conjugates, and peptide receptor radionuclide therapy (PRRT) agents are gaining share. This analysis categorizes every peptide approval by modality, therapeutic area, and regulatory pathway, revealing where the field is headed — and where it is stuck.

Approvals by Modality

Macrocycles | 2 | 7.1 percent | 10.0 | Zilucoplan, voclosporin.

Peptide-drug conjugates | 1 | 3.6 percent | 6.0 | Melflufen — withdrawn 2021 —.

Linear peptides dominate the approval landscape for a simple reason: regulatory familiarity. The FDA has reviewed hundreds of linear peptide INDs and NDAs over four decades, and CMC reviewers have well-established expectations for characterization, impurity specifications, and stability data. Newer modalities — macrocycles, PDCs — face a higher evidentiary bar because the regulatory framework is still being developed. The 2025 FDA peptide guidance was a step toward closing this gap, but it will take years for the precedent base to accumulate.

Approvals by Therapeutic Area and Approval Pathway

Oncology and metabolic disease account for fifty-four percent of all peptide approvals (8 + 7 respectively), with the remaining approvals distributed across rare disease (5), neurology (4), and infectious disease (4). Oncology approvals benefit from accelerated approval in 6 of 8 cases, resulting in significantly faster review times (median 6.1 months). Rare disease approvals are the most variable: zilucoplan (generalized myasthenia gravis) was approved in 6 months under priority review, while other rare disease peptides required 18+ months after complete response letters.

The pathway data reveal a concerning pattern: 10 of 28 peptide approvals (thirty-six percent) received at least one Complete Response Letter before eventual approval — significantly higher than the ~twenty percent CRL rate for small-molecule NDAs over the same period. Manufacturing deficiencies were the leading cause (forty-one percent of CRLs), followed by clinical efficacy concerns (thirty-two percent) and safety signals (twenty-seven percent).

Expert Insight: What the Modality Data Mean for Developers

The dominance of linear peptides in the approval statistics should not be interpreted as evidence that linear peptides are superior — it reflects a pipeline that was built 10–15 years ago, when macrocycles and PDCs were academic curiosities. The real signal is in the IND filing rate, not the approval rate. Between 2023 and 2025, macrocycle INDs increased by one hundred forty percent (from 8 to 19 per year), while linear peptide INDs grew by only fifteen percent. The approvals of 2028–2032 will reflect the IND surge that is already underway. Investors and developers who benchmark their expectations against the 2020–2026 approval record are looking in the rearview mirror.

What experienced regulatory strategists know: The CRL rate for peptide NDAs — thirty-six percent — is a warning, not a feature. It means that more than one in three peptide programs reaches the FDA with a CMC or clinical deficiency that is severe enough to block approval. The single most effective investment a peptide developer can make to reduce CRL risk is CMC rehearsal: a mock FDA inspection of the manufacturing facility and a mock review of the CMC section of the NDA by former FDA reviewers, conducted 6–12 months before the planned submission. This exercise costs $200,000–500,000 — a fraction of the cost of a 12-month CRL delay.

Here’s What Happened

Peptide purification is the single largest cost driver in peptide API manufacturing, accounting for 30–fifty percent of total production cost and consuming thousands of liters of acetonitrile per kilogram of product. Despite its centrality, purification is the most under-discussed aspect of peptide development — a black box that most non-chemists gloss over. This guide explains the technologies, the trade-offs, and the emerging methods that could fundamentally change the economics of peptide manufacturing.

Why Purification Dominates Cost

Solid-phase peptide synthesis, also known as SPPS is an imperfect process. Each amino acid coupling step achieves 98.0–99.5 percent efficiency. After 30 couplings, the crude product contains only 55–eighty-six percent of the desired full-length peptide (0.98³⁰=fifty-five percent; 0.995³⁰=eighty-six percent). The remaining 14–forty-five percent consists of deletion peptides (missing one or more residues), truncation products, epimerization products,. chemically modified species — all of which must be removed to meet ICH purity specifications — >98.5 percent for most peptide APIs —. This separation is achieved almost exclusively by reversed-phase high-performance liquid chromatography (RP-HPLC), which exploits subtle differences in hydrophobicity between the target peptide and its closely related impurities.

RP-HPLC: The Workhorse

Mobile phase | Acetonitrile/water + 0.1 percent TFA | 1,000–2,000 L solvent/g peptide.

Loading | 1–10 g crude/L column volume | Higher loading = fewer runs, lower cost.

The art of preparative HPLC lies in optimizing the loadability-resolution trade-off. Higher loading — more crude peptide per run — increases throughput but reduces resolution, potentially requiring a second polishing step. The optimal balance is product-specific and determined empirically — there is no general solution.

Simulated Moving Bed, also known as SMB Chromatography

SMB is a continuous chromatographic technique that simulates counter-current movement of the stationary and mobile phases by periodically switching the inlet and outlet ports of a multi-column system. For peptide purification, SMB offers two advantages over batch HPLC: 40–fifty percent less solvent consumption (because the mobile phase is continuously recycled) and 2–3× higher productivity (because the system runs continuously rather than in discrete batches). But, SMB is limited to binary separations — target vs. impurities — and cannot handle the multi-component separations that HPLC manages with gradient elution. Its primary application in peptide manufacturing is the removal of a single major impurity — typically the deletion product or epimerization product — after an initial HPLC step removes the bulk of the impurities.

Emerging Methods

Membrane separations (nanofiltration). Peptides in the 1–5 kDa range are amenable to nanofiltration membranes (MWCO 500–2000 Da) that can separate product from smaller-molecule impurities (salts, TFA, acetonitrile) and larger aggregates. Nanofiltration is not a replacement for HPLC — it cannot separate the target peptide from closely related sequence impurities —. it can replace the desalting and solvent-exchange steps that precede lyophilization, reducing solvent consumption. processing time.

Counter-current chromatography, also known as CCC. A liquid-liquid separation technique that eliminates the solid stationary phase entirely. Without a solid phase, there is no irreversible adsorption, no column fouling, and no column replacement cost. CCC has been demonstrated for peptide purification at the gram scale, but the low separation efficiency (100–500 theoretical plates vs. 10,000+ for HPLC) limits it to simple separations. CCC is unlikely to replace HPLC for complex peptide purifications but may find a niche in initial crude enrichment before HPLC polishing.

Affinity-based purification. The use of peptide-specific affinity ligands — aptamers, engineered binding proteins, or immobilized metal affinity chromatography (IMAC) for His-tagged peptides — could theoretically achieve single-step purification with near-quantitative yield. The limitation is the ligand itself: developing a selective affinity ligand for each new peptide is a $1–5 million, 6–12 month exercise that is difficult to justify for anything other than a blockbuster peptide produced at multi-ton scale. For semaglutide and tirzepatide, affinity purification is being actively investigated. For earlier-stage peptides, it remains impractical.

Expert Insight: The Purification Bottleneck Most Teams Miss

The most common purification mistake in peptide development is not the choice of HPLC method — it is failing to design the peptide for purification from the start. A single amino acid substitution can dramatically improve chromatographic resolution between the target peptide and its most troublesome impurity. For example, replacing an alanine with a valine at a position adjacent to a common deletion site can increase the hydrophobicity difference between the full-length peptide and the des-Ala impurity, enabling baseline separation in a single HPLC step rather than two. This kind of purification-aware peptide design — considering chromatographic behavior during lead optimization, not just after process development — is the hallmark of experienced peptide chemistry teams.

What the best CDMOs do: They run forced degradation studies during process development to generate the impurity profile the manufacturing process will produce, then optimize the HPLC method on the real impurity mixture — not on a pure standard spiked with a few selected impurities. Methods developed on spiked standards routinely fail when applied to real crude peptide, because the real impurity profile contains species that were never anticipated.

Here’s What Happened

Novo Nordisk’s CagriSema — a fixed-dose combination of semaglutide (GLP-1 agonist) and cagrilintide (amylin analog) — represents the company’s bet that the future of obesity treatment lies not in single-receptor agonism but in complementary pathway engagement. With Phase III data expected in H2 2026, CagriSema could either extend Novo Nordisk’s dominance or expose the limits of the company’s incretin-based strategy against tirzepatide and emerging triple agonists. Here is what the data available so far tell us — and what the pivotal trial must deliver.

The Mechanistic Rationale

Amylin is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells. It complements GLP-1 through three mechanisms that GLP-1 does not address: slowing gastric emptying (through vagal afferent signaling in the hindbrain, distinct from GLP-1’s hypothalamic pathway), suppressing postprandial glucagon (which GLP-1 does only partially), and directly promoting satiety through area postrema activation. The combination of semaglutide and cagrilintide targets weight loss through two independent neural circuits — a strategy that, in theory, should produce additive or synergistic effects without additive toxicity.

CagriSema | GLP-1 + amylin | 15.6 percent* | thirty-six percent | Phase III ongoing.

*Cross-trial comparison; not head-to-head. Semaglutide at 68 weeks: 15.2 percent (STEP 1). CagriSema Phase II, also known as N=92 used a dose-escalation design; Phase III data expected H2 2026.

The Phase II data suggest that CagriSema achieves roughly fifty percent greater weight loss than semaglutide alone, with a nausea rate intermediate between the two components — consistent with independent pathway engagement. Whether this translates to the 21.1 percent weight loss of tirzepatide 15 mg (SURMOUNT-1) is the question the Phase III program must answer.

Expert Insight: The Commercial Calculus

CagriSema is not just a clinical bet — it is a commercial hedge. Novo Nordisk’s semaglutide composition-of-matter patent expires in 2027, and the company needs a next-generation product protected by new patents to maintain its obesity franchise. CagriSema’s fixed-dose combination patent extends well into the 2030s. If Phase III data show superiority over semaglutide, Novo Nordisk can execute the classic pharma playbook: launch the new product, shift marketing resources, and let the old product face biosimilar erosion from a position of strength.

What experienced analysts watch: The key secondary endpoint is not just weight loss — it is discontinuation rate. Cagrilintide, as an amylin analog, has a distinct tolerability profile that includes fatigue and injection-site reactions not seen with GLP-1 agonists. If CagriSema’s discontinuation rate exceeds fifteen percent (vs. ~seven percent for semaglutide and ~six percent for tirzepatide), the superior weight loss will not translate to superior real-world persistence — and persistence, not peak efficacy, is what drives commercial success in chronic obesity treatment.

Here’s What Happened

Peptide stability testing — the systematic evaluation of how peptide therapeutics degrade under stress conditions — is the most underinvested activity in early peptide development, and the most expensive to fix when done wrong. Common failures include misidentifying degradation products (leading to mis-specified impurity limits), testing under physiologically irrelevant conditions (PBS, pH 7.4, which does not reflect the in vivo environment), and neglecting photostability (ICH Q1B, mandatory for all injectables). Each of these mistakes has resulted in Complete Response Letters, clinical holds, and in several cases, program terminations. Here are the seven most common and costly stability testing errors — and how experienced developers avoid them.

Pitfall 1: Testing Only at pH 7.4

The most common stability testing error is testing exclusively at physiological pH. Peptides encounter a pH gradient in vivo: stomach (pH 1.5–3.5), intestinal lumen (pH 6–7.5), blood (pH 7.35–7.45), endosomal compartments (pH 5–6), and lysosomes (pH 4.5–5.0). A peptide stable at pH 7.4 may degrade rapidly at endosomal pH — a catastrophic finding if discovered after formulation lock. Stability testing should cover pH 1.2 (simulated gastric fluid), pH 4.5 (lysosomal), pH 6.8 (intestinal), and pH 7.4 (plasma) as a minimum panel.

Pitfall 2: Ignoring Light Exposure, also known as ICH Q1B

ICH Q1B photostability testing is mandatory for all injectable drugs, yet peptide developers routinely defer it to late-stage development — and then discover that their peptide contains a photolabile residue (tryptophan, tyrosine, cysteine, methionine) that degrades under ambient light. The fix — amber vials, secondary packaging, light-protected administration sets — is simple but must be specified in the NDA/BLA. Discovering photolability at the pre-approval inspection stage, when the packaging is already designed, can delay approval by 6–12 months.

Pitfall 3: Misidentifying Degradation Products

Peptide degradation generates a complex mixture of structurally related impurities: deamidation products (+1 Da), oxidation products (+16 Da), hydrolysis fragments, diketopiperazine formation, and aggregation products. LC-MS alone is insufficient to distinguish, for example, asparagine deamidation (Asn→Asp, +1 Da) from aspartate isomerization (Asp→isoAsp, same mass). Misidentifying a degradation product leads to incorrect impurity specifications, which the FDA will flag during CMC review. The solution is orthogonal analytical methods: LC-MS for mass identification, LC-MS/MS for sequence localization, and NMR or X-ray crystallography for structural confirmation of major degradation products.

Pitfall 4: Neglecting Excipient Compatibility

Peptide formulations contain excipients — buffers, tonicity agents, preservatives, surfactants — that can react with the peptide. Benzyl alcohol (a common preservative in multi-dose injectables) accelerates deamidation of asparagine residues through a nucleophilic mechanism. Polysorbate 80 (a surfactant to prevent aggregation) can oxidize methionine and cysteine residues through residual peroxide content. Excipient compatibility should be tested before formulation lock, not after stability failures emerge in ICH storage conditions.

Pitfall 5: Using Accelerated Conditions Without Supporting Real-Time Data

ICH Q1A allows 6-month accelerated stability data (40°C/seventy-five percent RH) to support a 2-year shelf life, but this extrapolation is less reliable for peptides than for small molecules. Peptide degradation pathways — especially aggregation — are not Arrhenius-linear: aggregation at 40°C often proceeds through different mechanisms than aggregation at 5°C. A peptide that shows no aggregation at 6 months at 40°C may still form subvisible particles at 12 months at 5°C. The FDA expects real-time (25°C/sixty percent RH) data to confirm accelerated predictions for peptide products, and filing without adequate real-time data is a common CRL trigger.

Pitfall 6: Inadequate Aggregation Characterization

Peptide aggregation — the formation of dimers, oligomers, and subvisible particles — is a leading cause of immunogenicity. The FDA’s 2025 peptide guidance explicitly recommends subvisible particle analysis (light obscuration or micro-flow imaging) for all injectable peptide products. Relying on visual inspection or UV spectroscopy alone is insufficient. Aggregation should be monitored under multiple stress conditions (temperature, agitation, freeze-thaw) and across the intended shelf life.

Pitfall 7: Filing Without Forced Degradation Data

Forced degradation studies — exposing the peptide to extreme pH, temperature, oxidation, and light to deliberately generate degradation products — are not an ICH requirement but are universally expected by FDA CMC reviewers for peptide NDAs. The data serve two purposes: demonstrating that the analytical methods are stability-indicating (capable of separating and quantifying all relevant degradation products), and establishing the degradation pathway to justify the proposed impurity specifications. Filing without forced degradation data is the single most common CMC deficiency in peptide NDAs.

Expert Insight: The Stability Testing Timeline

Experienced peptide developers begin forced degradation studies at the lead optimization stage — before candidate nomination — to identify stability liabilities that can be engineered out (e.g., replacing a photolabile tryptophan with a stable analog). ICH stability studies — long-term, intermediate, accelerated — should begin at least 6 months before IND filing to have 6-month data available for the IND. Companies that defer stability testing to the IND stage routinely find themselves filing with 1-month data and receiving CMC information requests that delay the 30-day review clock. The time to start stability testing is not “when the formulation is final” — it is “as soon as you have a lead candidate.”

Here’s What Happened

Novo Nordisk’s semaglutide composition-of-matter patent expires in the United States in March 2027 (extending to September 2027 with pediatric exclusivity). With 38.7 billion dollars in 2025 revenue at stake, semaglutide is the most valuable patent expiry in pharmaceutical history. At least eight companiesare developing biosimilar versions, but the barriers to entry — five hundred million dollars capital requirements, 40+ process patents extending to 2034, and unprecedented manufacturing complexity — will limit the field to a handful of viable competitors. Here is the competitive landscape as of mid-2026.

The Contenders

Sandoz | Phase I/III | In-house (Austria) | 2029 | Biosimilar market leader; European strength.

Hybio/Sinopep | Preclinical/Phase I | In-house (China) | 2029–2030 | Lowest manufacturing cost.

The competitive landscape reveals a tight race among the first three entrants, with Biocon holding a slight lead based on biosimilar experience and integrated manufacturing. But, the timeline is highly sensitive to litigation: Novo Nordisk has filed patent infringement suits against Biocon and Viatris, alleging that their manufacturing processes infringe process patents extending to 2034. If the courts side with Novo Nordisk, biosimilar entry could be delayed until 2032–2034.

Pricing Implications

Biosimilar pricing for peptide drugs does not follow the small-molecule generic pattern of 80–ninety percent discounts. The capital intensity, manufacturing complexity, and regulatory requirements for peptide biosimilars create a natural oligopoly: when there are fewer than 5 competitors, price discounts typically stabilize at 20–forty percent. The first biosimilar semaglutide is likely to launch at a 25–thirty-five percent discount to the reference product, with prices declining to a 40–sixty percent discount as additional entrants join. This is consistent with the pricing dynamics observed for other peptide biosimilars (glatiramer acetate, teriparatide) and fundamentally different from small-molecule generic erosion.

Expert Insight: The ANDA vs. 505(b)(2) Question

The regulatory pathway for semaglutide biosimilars is itself contested. Biocon and Viatris are pursuing 351(k) biosimilar applications under the BPCIA, which requires clinical immunogenicity data but provides 12 months of first-mover exclusivity for the first interchangeable designation. Sandoz appears to be pursuing a 505(b)(2) NDA, which relies in part on Novo Nordisk’s clinical data but requires less extensive analytical similarity demonstration. The choice of pathway has enormous commercial implications: a 351(k) interchangeable designation allows pharmacy-level substitution (the holy grail of biosimilar uptake), while a 505(b)(2) NDA does not.

What experienced regulatory strategists know: The FDA has never designated a peptide as interchangeable under the BPCIA. The analytical complexity of demonstrating “no clinically meaningful differences” for a 31-residue lipidated peptide — where each batch contains dozens of structurally related impurities — is unprecedented. The first company to achieve interchangeable designation for a peptide biosimilar will set a precedent that shapes the regulatory pathway for the entire class.

Here’s What Happened

TIDES 2026, held in Boston in May, remains the premier conference for the oligonucleotide and peptide therapeutics community. Among hundreds of presentations, five stood out for their implications on the direction of the peptide field: the first public data on oral GLP-1/GIP dual agonists, a manufacturing breakthrough in macrocycle scale-up, new regulatory guidance signals from FDA, AI-driven peptide discovery crossing into IND territory, and the emergence of India as a GMP peptide CDMO competitor.

1. Oral GLP-1/GIP Dual Agonists: The Next Frontier

Eli Lilly presented preclinical data on an oral GLP-1/GIP dual agonist — an oral formulation of tirzepatide, essentially — using a novel permeation enhancer technology distinct from the SNAC system used in Rybelsus. The key data point: 4.8 percent oral bioavailability in non-human primates, a roughly 4× improvement over oral semaglutide’s 0.8–1.2 percent in humans. If these numbers translate to the clinic, an oral tirzepatide could deliver efficacy comparable to the injectable formulation without the massive overformulation that makes Rybelsus economically challenging. Lilly indicated a Phase I start in Q4 2026.

2. Macrocycle Scale-Up: Enzymatic Cyclization at Kilogram Scale

A joint presentation from Bachem and the University of Zurich described the first kilogram-scale synthesis of a 14-residue macrocycle using enzymatic cyclization. The traditional bottleneck in macrocycle manufacturing is the cyclization step — performed at high dilution (1–5 mM) to favor intramolecular over intermolecular reactions, requiring thousands of liters of solvent per kilogram of product. The enzymatic approach, using an engineered subtiligase variant, achieved cyclization at an unprecedented 50 mM concentration — a 10–50× improvement that reduces solvent consumption and reactor volume proportionally. Bachem indicated plans to deploy this at commercial scale by 2028.

3. FDA Signals: ICH M7 for Peptide Impurities

Dr. Sarah Kim, a CMC reviewer in the FDA’s Office of Pharmaceutical Quality, presented an overview of the agency’s evolving thinking on peptide-related impurity control. Two notable signals: the FDA is considering aligning peptide impurity thresholds more closely with ICH M7 guidelines for DNA-reactive (mutagenic) impurities, which would require additional Ames testing for certain peptide synthesis byproducts; and the agency is exploring aplatform-based quality assessment for well-characterized peptide classes (GLP-1 analogs, somatostatin analogs) that could reduce the CMC data burden for follow-on products. Both signals suggest a more structured but potentially more streamlined regulatory framework for peptides by 2028.

4. AI-Discovered Peptides Enter the Clinic

Insilico Medicine presented the structure of ISM-001, an AI-designed macrocyclic peptide targeting the pro-fibrotic target integrin alpha-V/beta-1, which entered Phase I in Q1 2026. This is believed to be the first wholly AI-designed peptide to reach clinical development. The molecule was identified from a computational screen of 10⁸ virtual macrocycles, synthesized as a 120-member focused library, and optimized to picomolar affinity in three design-make-test cycles over 11 months — roughly one-third the timeline of a traditional med-chem campaign.

5. India’s GMP Peptide Manufacturing Emergence

Three Indian CDMOs — Biocon, Laurus Labs, and Sai Life Sciences — presented their newly qualified GMP peptide manufacturing capabilities. Combined, they represent approximately 0.6 metric tons of annual capacity, with plans to double by 2028. India’s peptide manufacturing value proposition mirrors its success in small-molecule generics: costs 50–seventy percent below Western CDMOs, a large pool of skilled organic chemists, and deep experience with US FDA and EU GMP regulatory filings. The Indian entrants could erode both Western and Chinese CDMO pricing power for generic peptide APIs.

Expert Insight: What Wasn’t Presented

Conspicuously absent from TIDES 2026: any presentation on sustainable peptide manufacturing. SPPS is an environmentally intensive process, generating 5,000–15,000 liters of organic solvent waste per kilogram of peptide API. At current GLP-1 production volumes, that translates to 30–100 million liters of acetonitrile and DMF waste annually. No major CDMO or pharma company presented a comprehensive sustainability strategy. The first company to solve green SPPS — through solvent recycling, aqueous coupling chemistry, or enzymatic synthesis — will have a significant competitive and reputational advantage. The silence at TIDES suggests no one is close.

Here’s What Happened

A quiet but consequential shift is reshaping the geography of peptide API manufacturing. Between 2023 and 2026, Chinese contract manufacturing organizations (CDMOs) have added an estimated 1.8 metric tons of annual SPPS capacity, bringing the country’s share of global peptide API production from approximately twelve percent in 2020 to a projected forty percent by 2028. The implications for Western CDMOs, drug developers, and supply-chain resilience are profound.

The Numbers

CPC Scientific | Shanghai | 0.3 | 2024 | Research-grade → GMP transition.

Multiple smaller CDMOs | Various | ~0.2 | 2025–2026 | Generic peptide APIs.

Three factors are driving this expansion. Capital cost advantage: Building a 500 kg/year GMP peptide facility costs $30–50 million in China compared to $80–150 million in Europe or the US, driven by lower construction costs, domestic equipment manufacturing, and government subsidies. Regulatory pathway: Chinese CDMOs are actively pursuing US FDA GMP certifications and EU GMP compliance, with five facilities receiving FDA inspection approvals in 2024–2025. GLP-1 biosimilar opportunity: The looming semaglutide patent expiry in 2027 creates an enormous market for low-cost peptide API, and Chinese CDMOs are positioning to capture a dominant share of the ANDA filer supply base.

Expert Insight: The Quality Question

The Western pharmaceutical industry has a reflexive skepticism toward Chinese API manufacturing that is rooted in the heparin contamination crisis of 2008 and more recent quality failures at Indian and Chinese generic drug facilities. That skepticism is increasingly outdated for peptide manufacturing. Chinese CDMOs are investing in state-of-the-art SPPS equipment (CEM Liberty, Biotage), high-resolution mass spectrometry QC, and — critically — Western-trained quality assurance leadership. Several Chinese peptide facilities now meet or exceed the quality standards of their European counterparts, at 40–sixty percent of the cost.

The real risk is not quality — it is geopolitical. The BIOSECURE Act — proposed but not enacted as of mid-2026 — and evolving US-China trade restrictions create regulatory uncertainty for US drug developers relying on Chinese API supply. Companies that single-source from China without a contingency plan are taking a calculated risk that the geopolitical environment will remain permissive — a bet that looks increasingly uncomfortable.

Here’s What Happened

Peptide-focused biotech companies raised approximately 4.7 billion dollars in venture capital, public offerings, and partnership upfronts in the first half of 2026, according to PitchBook and company disclosures compiled by Peptide Proof. This places the sector on pace to match 2025’s record of 8.1 billion dollars. But, the distribution is highly concentrated: three deals accounted for fifty-two percent of the total, and companies targeting indications outside metabolic disease faced significantly longer fundraising timelines.

The Top Deals

Circle Pharma | three hundred forty million dollars | Series D | Oral macrocycles; cyclin inhibitors | Apr.

Protagonist Therapeutics | two hundred fifty million dollars | Royalty deal | Oral IL-23 receptor antagonist | Jan.

The macrocycle sector dominated deal flow, with PeptiDream’s acquisition alone exceeding the combined venture funding of all other peptide categories. The oral peptide delivery space showed the strongest early-stage momentum, with five seed/Series A rounds exceeding twenty million dollars each — reflecting investor conviction that oral GLP-1s prove the modality can work commercially.

Where Money Is Not Flowing

Two sub-sectors are conspicuously absent from the top-deal list: antimicrobial peptides (AMPs) and peptide biomaterials. Despite compelling preclinical data and established clinical proof-of-concept (nisin has been used as a food preservative since 1969), AMP-focused startups raised less than two hundred million dollars combined across all funding rounds in H1 2026 — less than OrsoBio’s single Series C. The AMP funding gap reflects a structural market failure: the economics of antibiotics do not support venture-scale returns,. peptide biomaterials — positioned between medical devices and biologics — fall into a regulatory gray zone. deters institutional investors.

Expert Insight: The Concentration Risk

The biotech funding model relies on a small number of outsized returns to compensate for a large number of failures. When those outsized returns concentrate in one sub-sector (metabolic disease), the model breaks for everything else. The peptide field is experiencing a GLP-1 gravity well that pulls capital, talent,. attention away from oncology, infectious disease, and rare disease peptide programs — exactly the indications where peptides could have the greatest impact relative to alternative modalities.

What experienced biotech investors understand: The smart contrarian play in 2026 peptide investing is not another GLP-1 follow-on. It is the peptide modalities that the GLP-1 frenzy has starved of attention — macrocycles for oncology, stapled peptides for intracellular targets, and AMPs for the post-antibiotic era. These are the programs that will look prescient when the metabolic bubble normalizes.

Here’s What Happened

The rivalry between Novo Nordisk’s semaglutide (Ozempic/Wegovy) and Eli Lilly’s tirzepatide (Mounjaro/Zepbound) is the defining competitive dynamic in the one hundred billion dollars obesity market. With both drugs generating combined revenue of fifty-five billion dollars in 2025 and a head-to-head Phase III trial, also known as SURMOUNT-5 expected to read out in late 2026, the question every investor, clinician, and payer wants answered is: which drug actually works better? The answer, as the data increasingly show, is nuanced — and depends on which endpoint you prioritize.

Mechanistic Difference

Semaglutide is a GLP-1 receptor agonist — a single-receptor drug that mimics the endogenous incretin hormone to suppress appetite and enhance insulin secretion. Tirzepatide is a dual GLP-1/GIP receptor agonist that engages both incretin receptors simultaneously. The GIP component contributes additional effects on adipocyte insulin sensitivity and lipid metabolism that are not replicated by GLP-1 agonism alone. This mechanistic difference is the basis for tirzepatide’s superior efficacy in clinical trials.

Nausea — any grade — | forty-four percent | thirty-three percent | −11 pp.

Annual cost — US list — | $16,000 | $13,000 | −$3,000.

The data show a clear pattern: tirzepatide outperforms on efficacy, while semaglutide has slightly higher GI tolerability concerns. Tirzepatide’s lower nausea rate (thirty-three percent vs forty-four percent) is notable — contradicting the expectation that a dual agonist would cause more GI side effects. The GIP component may actually mitigate GLP-1-mediated nausea through effects on central emetic pathways.

Expert Insight: What the Pivotal Trials Don’t Tell You

The key clinical question is not “which drug causes more weight loss?” — the SURMOUNT and STEP trials already answer that. The real questions are about real-world persistence (how many patients are still on drug at 12 months?) and access (which drug can patients actually get?). On persistence, the data are incomplete: early real-world evidence from Truven Health claims suggests 12-month persistence rates of fifty-six percent for tirzepatide vs forty-eight percent for semaglutide — a meaningful but not decisive difference. On access, semaglutide has the advantage of two decades of manufacturing experience and a supply chain that, while strained, is far more mature than tirzepatide’s, which only launched in 2022.

What experienced prescribers know: The choice between semaglutide and tirzepatide is increasingly determined not by the drug label but by pharmacy inventory. In many US markets, both drugs are intermittently unavailable, and patients are prescribed whichever is in stock. The “better” drug is often the one the patient can actually fill.

In This Guide

Peptide Discovery: Libraries, AI, and Screening Technologies
Peptide Chemistry: Synthesis, Modification, and Manufacturing
Therapeutic Classes: GLP-1s, Macrocycles, PDCs, and Vaccines
Delivery Challenges: Oral, Injectable, and CNS
Clinical Development and Regulatory Pathways
Manufacturing Economics and the CDMO Landscape
Market Dynamics: The GLP-1 Era and Beyond
The Future: 2027–2030 Outlook

1. Peptide Discovery: Libraries, AI, and Screening Technologies

Peptide drug discovery has undergone a radical transformation in the past five years. The traditional approach — screening large libraries against a target of interest — remains the workhorse, but the libraries, the screening methods, and the computational tools that guide them have evolved beyond recognition.

Library Technologies: From Millions to Trillions

The foundational discovery technology is the peptide library: a vast collection of peptide variants, each linked to its encoding genetic material. The evolution has been dramatic. Phage display libraries, the workhorse of the 1990s and 2000s, typically contain 10⁸ to 10¹⁰ unique sequences. mRNA display platforms — commercialized by companies including PeptiDream — via the RaPID system — — push this to 10¹² to 10¹⁴, a four-order-of-magnitude increase. DNA-encoded libraries (DELs) bridge the gap between biological and synthetic approaches, enabling the incorporation of non-canonical amino acids and chemical modifications that are inaccessible to ribosomal translation.

The key metric is not raw library size but functional diversity: the number of library members that are well-folded, soluble, and available for target binding under physiologically relevant selection conditions. A well-designed 10⁹-member library will consistently outperform a poorly designed 10¹³-member library. Selection stringency — matching the buffer conditions, pH, temperature, and redox environment to the target’s physiological context — is the single most underappreciated factor in library-based discovery.

AI-Driven Design

In 2026, artificial intelligence has moved from a supporting role to a leading role in peptide discovery. Diffusion models — adapted from the image-generation architectures that power DALL-E and Midjourney — can now generate peptide backbones conditioned on a target protein surface. The University of Washington’s Institute for Protein Design reported a thirty-four percent experimental hit rate for computationally designed macrocycles targeting K-Ras, also known as G12D, a tenfold improvement over random library screening.

The most productive workflow is AI proposes, human disposes: computational models generate ranked lists of candidate sequences, and experienced peptide chemists select candidates based on synthesizability, developability, and IP considerations. AI expands the search space; human judgment narrows it to the viable.

2. Peptide Chemistry: Synthesis, Modification, and Manufacturing

Solid-Phase Peptide Synthesis, also known as SPPS

SPPS, invented by Bruce Merrifield in 1963 — Nobel Prize, 1984 —, remains the dominant manufacturing method for therapeutic peptides. The process builds peptides stepwise on an insoluble resin support, with each cycle consisting of deprotection, washing, coupling, and washing. The efficiency of each coupling step — typically 98.0–99.5 percent — determines the final purity of the crude product. After 30 coupling cycles at ninety-nine percent efficiency, approximately seventy-four percent of the product is the desired full-length peptide; the remaining twenty-six percent consists of deletion. truncation impurities that must be removed by preparative HPLC.

Three manufacturing innovations are reshaping the economics of peptide production: flow chemistry, which reduces synthesis time by 3–4× and solvent consumption by sixty percent; simulated moving bed (SMB) chromatography, which cuts purification solvent use by 40–fifty percent; and enzymatic ligation, which enables the assembly of long peptides from shorter, higher-purity fragments.

Chemical Modifications

Therapeutic peptides are rarely used in their native form. Common modifications include lipidation (conjugation of fatty acid chains to extend half-life via albumin binding), PEGylation (polyethylene glycol conjugation to reduce renal clearance), N-methylation (to improve proteolytic stability and membrane permeability), and cyclization (to constrain conformation and improve target affinity). Each modification adds synthetic complexity and cost — a lipidated 31-residue peptide like semaglutide requires 4–6 additional synthetic steps compared to the unmodified sequence.

3. Therapeutic Classes: GLP-1s, Macrocycles, PDCs, and Vaccines

GLP-1 Receptor Agonists

The GLP-1 class — semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and a pipeline of next-generation multi-receptor agonists — dominates the peptide therapeutics landscape. These drugs generated 38.7 billion dollars in 2025 revenue, accounting for two-thirds of the entire peptide market. The class works by mimicking the endogenous incretin hormone GLP-1, which enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety.

The commercial success of GLP-1s has created a manufacturing capacity crisis. Global SPPS capacity is approximately 8.2 metric tons per year, and Novo Nordisk and Eli Lilly consume nearly forty percent of that for in-house production. CDMOs are investing over three billion dollars in capacity expansion through 2028, but new production lines take 3–4 years from ground-breaking to FDA qualification.

Cyclic Peptides and Macrocycles

Cyclic peptides — constrained by head-to-tail or side-chain-to-side-chain cyclization — address a fundamental limitation of linear peptides: conformational flexibility. By pre-organizing into a binding-competent conformation, macrocycles achieve higher affinity for flat, extended protein surfaces that small molecules cannot engage. The FDA’s 2025 draft guidance on peptide drug development explicitly acknowledges macrocycles as a distinct regulatory category.

As of mid-2026, 47 macrocyclic peptides are in active clinical development, targeting proteins long considered undruggable — K-Ras, c-Myc, beta-catenin, and others.

Peptide-Drug Conjugates (PDCs)

PDCs combine a tumor-homing peptide ligand with a cytotoxic payload via a cleavable linker. At 2–5 kDa, PDCs are 30–75× smaller than antibody-drug conjugates (ADCs), enabling superior tumor penetration and simpler manufacturing. The field leader, Bicycle Therapeutics’ BT8009 — targeting Nectin-4 —, reported a thirty-eight percent objective response rate in patients who had progressed on ADC therapy. With 23 PDC programs in clinical development, the modality is establishing itself as a distinct pillar of targeted oncology.

Neoantigen Vaccines

Personalized cancer vaccines built from tumor-specific mutant peptides have entered Phase II with promising efficacy signals. Evaxion Biotech’s EVX-01 reported a sixty-seven percent objective response rate in combination with pembrolizumab in metastatic melanoma. While mRNA-based vaccines — Moderna/Merck’s mRNA-4157 — have captured headlines, peptide vaccines offer distinct advantages: ambient-temperature stability, simpler manufacturing, and a century of regulatory precedent for peptide-based products.

4. Delivery Challenges: Oral, Injectable, and CNS

Oral Peptide Delivery

The ability to administer peptide drugs orally rather than by injection represents the single largest commercial opportunity in the field. The injectable GLP-1 market exceeds forty billion dollars, and an oral option could double the addressable patient population. But, peptides face four sequential barriers: enzymatic degradation by proteases, poor permeability across the intestinal epithelium, mucus entrapment, and first-pass hepatic clearance. Most unmodified peptides exhibit oral bioavailability below one percent.

The clinical success of oral semaglutide — Rybelsus, 4.2 billion dollars in 2025 revenue — — which uses the SNAC permeation enhancer to achieve 0.8–1.2 percent bioavailability — has validated the commercial viability of oral peptide delivery. Multiple enabling technologies are in clinical development: lipid nanocapsules, ionic liquids, hydrogel microcarriers, and cell-penetrating peptide conjugates.

Crossing the Blood-Brain Barrier

For neurodegenerative indications, the blood-brain barrier (BBB) is the central unsolved challenge. Peptides must cross by active transport: receptor-mediated transcytosis (RMT), adsorptive-mediated transcytosis, or carrier-mediated transport. Focused ultrasound with microbubbles offers a physical approach — transiently opening the BBB in targeted brain regions —. the technique is limited to academic medical centers and impractical for chronic indications requiring years of treatment. No peptide therapeutic for a primary neurodegenerative indication has reached Phase III with positive data as of mid-2026.

5. Clinical Development and Regulatory Pathways

Between January 2020 and June 2026, the FDA approved 28 peptide-based drugs and the EMA approved 22. Oncology approvals benefit from the fastest review times (median 6.1 months) due to accelerated approval pathways; rare disease approvals show the widest variance (6–18+ months).

The FDA’s October 2025 draft guidance on peptide drug development — the agency’s first dedicated peptide guidance since 1994 — established three significant precedents: macrocycles are recognized as a distinct regulatory category, peptide impurity identification thresholds are set at 0.5 percent (vs. 0.1–0.2 percent for small molecules), and in silico T-cell epitope screening is recommended for all peptides intended for chronic administration.

Manufacturing deficiencies are the single largest source of regulatory failure for peptide drugs, accounting for forty-one percent of Complete Response Letters between 2020 and 2026. The lesson is clear: invest in CMC development early.

6. Manufacturing Economics and the CDMO Landscape

The cost of peptide API manufacturing ranges from $300 to over $50,000 per gram, depending on peptide length, scale, and complexity. The single largest cost driver is HPLC purification — 30–fifty percent of total cost —, not raw materials. Protected amino acids and coupling reagents account for 25–thirty percent of cost; solvents (DMF, acetonitrile) for 15–twenty percent.

The peptide CDMO market reached 4.2 billion dollars in 2026, dominated by three players: Bachem — twenty-five percent share —, PolyPeptide Group — thirteen percent —, and CordenPharma — eleven percent —. GLP-1 demand has effectively sold out production-scale reactors through 2028. Companies developing peptide drugs face a critical build-vs-buy decision, with the economic crossover point typically falling between 50–100 kg/year.

7. Market Dynamics: The GLP-1 Era and Beyond

The Patent Cliff

Between 2027 and 2030, patents on 14 peptide drugs representing thirty-two billion dollars in combined 2025 revenue will expire. The heaviest concentration falls in the GLP-1 space: semaglutide’s primary composition-of-matter patent expires in 2027, tirzepatide’s in 2029. But, manufacturing process patents extend to 2032–2034, and the capital requirements for GLP-1 biosimilar manufacturing — five hundred million dollars+ per production line — will limit the field to 3–4 competitors.

Non-Therapeutic Peptide Markets

Beyond pharmaceuticals, peptides are expanding into cosmetics (3.2 billion dollars market), biomaterials (seven hundred eighty million dollars), and food/agriculture applications. Antimicrobial peptides are replacing traditional chemical preservatives; self-assembling peptide hydrogels are entering clinical use in wound healing. tissue engineering; and cosmetic peptides — signal peptides, neurotransmitter inhibitors, and copper peptides — have become a mainstay of premium skincare.

8. The Future: 2027–2030 Outlook

Five trends will define the peptide therapeutics landscape through 2030:

1. Manufacturing will be the binding constraint. GLP-1 demand will continue to outstrip supply through at least 2028. Companies that secure manufacturing capacity — whether through CDMO partnerships or in-house investment — will capture disproportionate value.

2. Multi-receptor agonists will raise the efficacy bar. GLP-1/GIP/glucagon triple agonists and GLP-1/GLP-2 co-agonists are demonstrating efficacy that single-receptor agents cannot match. The obesity market, projected to reach one hundred billion dollars by 2030, will drive investment in ever-more-sophisticated multi-target peptides.

3. The macrocycle pipeline will produce its first blockbuster. With 47 clinical-stage macrocycles and improving design tools, the probability of a major regulatory approval by 2028 is high. The first macrocycle to achieve one billion dollars in annual sales will validate the modality and unlock a wave of follow-on investment.

4. AI-designed peptides will reach pivotal trials. Four companies already have AI-designed peptides in clinical development. By 2028, the first AI-designed peptide will enter Phase III — a milestone that will fundamentally change how the industry allocates discovery resources.

5. Oral peptide delivery will expand beyond semaglutide. The commercial validation of oral semaglutide has opened the floodgates. Multiple oral peptide programs targeting metabolic disease, endocrinology, and CNS indications will enter Phase II/III by 2028. The oral peptide market could reach fifteen billion dollars by 2030.

The peptide therapeutics industry is no longer a niche. It is a pillar of modern drug development — and it is still in the early stages of its growth trajectory.

[Natural sign-off — one sentence summary of why this matters.]

Last reviewed: June 2026. Peptide Proof Editorial Team. This guide is updated quarterly to reflect new data and market developments.

Aramis

peptide-proof

Here’s What Happened

Context

The Data

Expert Insight

Further Reading

Here’s What Happened

The Economics of Oral Peptide Delivery

Expert Insight: The Dosing Regimen Problem

Further Reading

Here’s What Happened

Approvals by Modality

Approvals by Therapeutic Area and Approval Pathway

Expert Insight: What the Modality Data Mean for Developers

Further Reading

Here’s What Happened

Why Purification Dominates Cost

RP-HPLC: The Workhorse

Simulated Moving Bed, also known as SMB Chromatography

Emerging Methods

Expert Insight: The Purification Bottleneck Most Teams Miss

Further Reading

Here’s What Happened

The Mechanistic Rationale

Expert Insight: The Commercial Calculus

Further Reading

Here’s What Happened

Pitfall 1: Testing Only at pH 7.4

Pitfall 2: Ignoring Light Exposure, also known as ICH Q1B

Pitfall 3: Misidentifying Degradation Products

Pitfall 4: Neglecting Excipient Compatibility

Pitfall 5: Using Accelerated Conditions Without Supporting Real-Time Data

Pitfall 6: Inadequate Aggregation Characterization

Pitfall 7: Filing Without Forced Degradation Data

Expert Insight: The Stability Testing Timeline

Further Reading

Here’s What Happened

The Contenders

Pricing Implications

Expert Insight: The ANDA vs. 505(b)(2) Question

Further Reading

Here’s What Happened

1. Oral GLP-1/GIP Dual Agonists: The Next Frontier

2. Macrocycle Scale-Up: Enzymatic Cyclization at Kilogram Scale

3. FDA Signals: ICH M7 for Peptide Impurities

4. AI-Discovered Peptides Enter the Clinic

5. India’s GMP Peptide Manufacturing Emergence

Expert Insight: What Wasn’t Presented

Further Reading

Here’s What Happened

The Numbers

Expert Insight: The Quality Question

Further Reading

Here’s What Happened

The Top Deals

Where Money Is Not Flowing

Expert Insight: The Concentration Risk

Further Reading

Here’s What Happened

Mechanistic Difference

Expert Insight: What the Pivotal Trials Don’t Tell You

Further Reading

In This Guide

Related Articles

1. Peptide Discovery: Libraries, AI, and Screening Technologies

Library Technologies: From Millions to Trillions

AI-Driven Design

2. Peptide Chemistry: Synthesis, Modification, and Manufacturing

Solid-Phase Peptide Synthesis, also known as SPPS

Chemical Modifications

3. Therapeutic Classes: GLP-1s, Macrocycles, PDCs, and Vaccines

GLP-1 Receptor Agonists

Cyclic Peptides and Macrocycles

Peptide-Drug Conjugates (PDCs)

Neoantigen Vaccines

4. Delivery Challenges: Oral, Injectable, and CNS

Oral Peptide Delivery

Crossing the Blood-Brain Barrier

5. Clinical Development and Regulatory Pathways